Published in Pain and Central Nervous System Week, August 20th, 2007
"Rob's extensive experience in the pharmaceutical industry, particularly in neurologic disorders, and his expertise in leading clinical trials will be invaluable to Medivation as we advance Dimebon through clinical development," said David Hung, M.D., president and chief executive officer of Medivation. "His addition to our senior management team comes at a pivotal time as we recently completed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week